Medtronic R&D Spending Shifts To Neuromodulation, Diabetes
This article was originally published in The Gray Sheet
Executive Summary
Medtronic is allocating an increasing share of R&D resources to its high-growth neuromodulation and diabetes care segments, at the expense of its larger but slower-growing cardiac rhythm disease management and cardiovascular care businesses
You may also be interested in...
Medtronic Consolidates Units Into Two Broad Groups
Medtronic says it hopes to improve efficiency by restructuring its businesses into two groups
Medtronic Consolidates Units Into Two Broad Groups
Medtronic says it hopes to improve efficiency by restructuring its businesses into two groups
Psychiatric Devices: Medtronic OCD Approval, Depression Trial Announced
The medical device industry took another step into the field of psychiatry Feb. 19 with FDA's humanitarian device exemption of Medtronic's Reclaim deep brain stimulator for treating patients with severe obsessive-compulsive disorder